Vitamin K Oral Solution Recalled for CGMP Deviations
Edge Pharma is recalling 757 syringes of Vitamin K Oral Solution nationwide due to CGMP (Current Good Manufacturing Practice) deviations identified during manufacturing. The recall was initiated voluntarily by the firm and has been terminated.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source classifies this as FDA Class II with no reported illnesses or injuries. The hazard is manufacturing process deviations (CGMP non-compliance) rather than confirmed contamination or a known risk of harm. Per the rubric, Class II recalls without hospitalization reports typically score 2 (Moderate).
Plain-English summary
Edge Pharma, LLC is recalling Vitamin K (Vitamin K) Oral Solution (PF), 5 mg/mL, supplied in 1 mL per syringe single-dose syringes for oral use. A total of 757 syringes have been distributed nationwide. The product is manufactured by Edge Pharma, LLC, located at 856 Hercules Drive, Colchester, Vermont.
The recall was initiated due to CGMP (Current Good Manufacturing Practice) deviations identified during the manufacturing process. This is a voluntary recall initiated by the firm, with the FDA classifying it as a Class II recall. The recall was reported on February 2, 2022, and the recall initiation date was December 6, 2021.
Affected lots were distributed between October 27, 2021 and December 1, 2021, with specific lot codes 10-2021-11@6 (dated 01-09-2022, distribution period 10/27/21 - 11/16/21) and 11-2021-01@8 (dated 01-30-2022, distribution period 11/16/21 - 12/01/21). The product is identified by NDC 05446-1132-03. Patients and healthcare providers should contact Edge Pharma, LLC or their pharmacy regarding this recall. The recall has been terminated as of June 7, 2023.
The recalled product
- Product
- Vitamin K (Vitamin K ) Oral Solution (PF), 5 mg/mL, 1mL per syringe, single Dose Syringe for Oral Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1132-03
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Vitamin / Nutritional
- Affected units
- 757
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 56 recalled by Edge Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Edge Pharma, LLC
See all →- ModerateProfound-PE Dental Gel Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
- SevereMVASI Sterile Ophthalmic Solution Lacks Assured Sterility
FDA (Drugs) · 2022-02-02
- ModerateLET Topical Gel drug recall for CGMP deviations
FDA (Drugs) · 2022-02-02
- SevereVancomycin HCl Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2022-02-02
- ModerateCSF-HC Otic Powder Drug Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09